Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 257Carcinoma, Non-Small-Cell Lung 213Ovarian Neoplasms 134Lung Neoplasms 107Esophageal Neoplasms 69Triple Negative Breast Neoplasms 64Stomach Neoplasms 58Fallopian Tube Neoplasms 56Squamous Cell Carcinoma of Head and Neck 52Neoplasm Metastasis 50Head and Neck Neoplasms 44Esophageal Squamous Cell Carcinoma 43Carcinoma, Ovarian Epithelial 42Neoplasms 36Endometrial Neoplasms 34Uterine Cervical Neoplasms 32Recurrence 29Adenocarcinoma Of Esophagus 24Adenocarcinoma of Lung 22Urinary Bladder Neoplasms 21Melanoma 20Carcinoma, Squamous Cell 19Carcinoma 18Small Cell Lung Carcinoma 17Prostatic Neoplasms 15Breast Neoplasms, Male 15Adenocarcinoma, Bronchiolo-Alveolar 13Peritoneal Neoplasms 12Inflammatory Breast Neoplasms 12Testicular Neoplasms 10

Interventions

adavosertib 1Paclitaxel 1Gemcitabine 1Carboplatin 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation × Paclitaxel × Clear all
NCT02272790 2023-10-03

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

AstraZeneca

Phase 2 Completed
95 enrolled 61 charts
Gynecologic

Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡